AT A GLANCE
IP: PCT submitted in Sep. 2016, received exceptionally positive search report and written opinion
- Provides full-body embolic protection
- No additional arterial access required
- Performs deﬂection, capture and removal of embolic particles
- Easy and intuitive deployment and retrieval
- Protects aorta surface
- Stable and safe device anchoring
- No interference to procedure devices
- Applicable for a variety of procedures
The worldwide TAVI market is estimated to surpass $5.5B by 2020. Additional major markets include TMVR (estimated at five times of the TAVI market) and AF Ablation (1.2M procedures annually). The total addressable market for Filterlex is valued at over $5B.
During catheter-based, left-heart procedures such as TAVI, embolic particles are often released to the blood ﬂow. Particles migration to the brain may cause a spectrum of neurological defciencies, from cognitive impairment to debilitating stroke. Emboli released to distal organs may result in acute kidney injury and ischemia.
The Filterlex device is a next-generation full-body embolic protection device, easily and intuitively deployed and retrieved. The device is securely positioned in the aorta, protects its surface while facilitating a seamless TAVI procedure. Its distinctive, triple action design provides a full-body embolic protection by deﬂecting, capturing and removing embolic particles. Uniquely, it requires no additional arterial access and does not interfere to the procedure workﬂow.